Luke Timmerman

People are returning to the office. Many are rethinking the basics of work. So many people are exhausted and anxious. Biotech leaders are thinking carefully about how to proceed. An R&D-based industry needs people in environments that allow them to be energized, creative, collaborative. Here’s one simple idea: Walking meetings. The “walk and talk” business meeting isn’t new. But we... Read More

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.   Subscribe Now   Sign in to your account.

Clinical trialists are always trying to come up with catchy study titles. I’m not a big fan of these acronyms, and try to avoid using them. They’re often forgettable. But this week I saw one that stood out as especially meaningful. Yale University researchers are running a new Long COVID study. It’s called – LISTEN. It stands for Listen to... Read More

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.   Subscribe Now   Sign in to your account.

Climbing Mt. Everest changed my life. The world’s highest mountain required digging deep — physically, mentally, emotionally. That was four years ago. That original climb was a success, raising $340,000 for cancer research at the Fred Hutchinson Cancer Research Center. But what came next meant more. The climb opened my mind to new ways of making a contribution, in addition... Read More

Not long ago, biotech leaders steered clear of commenting on the issues of the day. Politics was limited to certain vested interests like drug pricing, science funding, and FDA regulation. Then came COVID-19 and the racial justice reckoning. Staring these terrible things in the face, people began to think more about their roles in the workplace, and in the community.... Read More

Every thriving biotech hub can trace its origins to one or two outstanding scientific institutions. But every thriving region can also trace some of its success back to community leaders. These are people who attend boring night meetings. They aren’t household names. They’re fine with that. These people were especially common in America after World War II. They laid down... Read More

The future of biotech isn’t limited to a few square miles in Cambridge, Mass. and South San Francisco. Biotech is starting to spread its wings in minor league towns. That’s good news. It’s also necessary for the industry to grow and continue to better integrate into the wider world. Let’s look at an example close to my home in Seattle.... Read More

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.   Subscribe Now   Sign in to your account.